FDA Unveils Plan for Real-Time Review of Clinical Trial Data

Read the article here.

The FDA just announced a pilot program that could meaningfully reshape how drugs are developed and reviewed. Under this initiative, regulators can view safety and efficacy signals from ongoing clinical trials in real time, rather than waiting for full data lock and submission. Importantly, this isn’t about bypassing rigor. Prevail InfoWorks has been providing sponsors with this ability across 8 FDA approvals. When executed well, real-time trials reduce administrative burden without compromising data quality. The FDA soliciting feedback and discussing AI-enhanced early trials should be viewed as a major step forward. Anyone who has worked with us knows that the real-time data from the Prevail approach has an outsized downstream impact on development timelines, clinical and corporate objectives, and capital efficiency.